amitriptyline has been researched along with Peripheral Nerve Diseases in 44 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a randomized, double-blind, placebo-controlled, crossover study at a single center in South Africa, to ascertain whether amitriptyline is an effective analgesic for painful HIV-associated sensory neuropathy of moderate to severe intensity in: i) antiretroviral drug naive individuals, and ii) antiretroviral drug users." | 9.20 | Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy. ( Dinat, N; Kamerman, PR; Marinda, E; Moch, S; Rice, AS, 2015) |
| "Oral amitriptyline, a tricyclic antidepressant, is effective for treating neuropathic pain." | 9.13 | Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. ( Ho, KY; Huh, BK; Miller, EJ; White, WD; Yeh, CC, 2008) |
| "Little is known about the effects of low doses of amitriptyline, prescribed in the treatment of neuropathic pain, on attentional processing capacity." | 9.12 | Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings. ( Kalkman, CJ; Kenemans, JL; Olivier, B; van Wijck, AJ; Veldhuijzen, DS; Volkerts, ER, 2006) |
| "The acute and subchronic effects of low doses nocturnally administered amitriptyline were compared to placebo in a double-blind crossover randomized study on driving ability and driving-related skills involving seven chronic neuropathic pain patients." | 9.12 | Acute and subchronic effects of amitriptyline 25mg on actual driving in chronic neuropathic pain patients. ( Kalkman, CJ; Kenemans, JL; Olivier, B; van Wijck, AJ; Veldhuijzen, DS; Verster, JC; Volkerts, ER, 2006) |
| "To compare amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics." | 9.08 | A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. ( Arnqvist, H; Boivie, J; Holmgren, H; Lindström, T; Thorell, LH; Vrethem, M, 1997) |
| "To evaluate the efficacy of a standardized acupuncture regimen (SAR) and amitriptyline hydrochloride for the relief of pain due to HIV-related peripheral neuropathy in HIV-infected patients." | 9.08 | Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. ( Brizz, B; Chaloner, K; Cohn, DL; Flaws, B; Hillman, S; Max, MB; Reichelderfer, P; Shlay, JC; Wentworth, D, 1998) |
| "We conducted a randomized, double-blind, placebo-controlled, crossover study at a single center in South Africa, to ascertain whether amitriptyline is an effective analgesic for painful HIV-associated sensory neuropathy of moderate to severe intensity in: i) antiretroviral drug naive individuals, and ii) antiretroviral drug users." | 5.20 | Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy. ( Dinat, N; Kamerman, PR; Marinda, E; Moch, S; Rice, AS, 2015) |
| "Oral amitriptyline, a tricyclic antidepressant, is effective for treating neuropathic pain." | 5.13 | Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. ( Ho, KY; Huh, BK; Miller, EJ; White, WD; Yeh, CC, 2008) |
| "Little is known about the effects of low doses of amitriptyline, prescribed in the treatment of neuropathic pain, on attentional processing capacity." | 5.12 | Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings. ( Kalkman, CJ; Kenemans, JL; Olivier, B; van Wijck, AJ; Veldhuijzen, DS; Volkerts, ER, 2006) |
| "The acute and subchronic effects of low doses nocturnally administered amitriptyline were compared to placebo in a double-blind crossover randomized study on driving ability and driving-related skills involving seven chronic neuropathic pain patients." | 5.12 | Acute and subchronic effects of amitriptyline 25mg on actual driving in chronic neuropathic pain patients. ( Kalkman, CJ; Kenemans, JL; Olivier, B; van Wijck, AJ; Veldhuijzen, DS; Verster, JC; Volkerts, ER, 2006) |
| "To compare amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics." | 5.08 | A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. ( Arnqvist, H; Boivie, J; Holmgren, H; Lindström, T; Thorell, LH; Vrethem, M, 1997) |
| "To evaluate the efficacy of a standardized acupuncture regimen (SAR) and amitriptyline hydrochloride for the relief of pain due to HIV-related peripheral neuropathy in HIV-infected patients." | 5.08 | Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. ( Brizz, B; Chaloner, K; Cohn, DL; Flaws, B; Hillman, S; Max, MB; Reichelderfer, P; Shlay, JC; Wentworth, D, 1998) |
| " administration of either of two antidepressants used for the treatment of neuropathic pain, amitriptyline (10 mg/kg) and fluoxetine (5 mg/kg), to rats for 7 days modifies GABA(B) receptor function and subunit expression in the lumbar spinal cord." | 3.73 | GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. ( Duric, V; Enna, SJ; McCarson, KE; Reisman, SA; Winter, M, 2006) |
| "To describe our experience with chronic sensory neuropathic cough and its response to amitriptyline in a first group of patients." | 3.73 | Sensory neuropathic cough: a common and treatable cause of chronic cough. ( Bastian, RW; Delsupehe, KG; Vaidya, AM, 2006) |
| "Amitriptyline was well tolerated." | 2.73 | Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. ( Haanpää, M; Kalso, E; Kautio, AL; Saarto, T, 2008) |
| "Six children with cerebral palsy are presented who developed neuropathic pain following multilevel orthopedic surgery." | 1.33 | Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. ( Lauder, GR; White, MC, 2005) |
| "Amitriptyline is a tricyclic antidepressant that is historically indicated and used to manage depression." | 1.33 | Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. ( Dukes, E; Gore, M; Leslie, DL; Rowbotham, D; Tai, KS, 2006) |
| "We report peripheral paresthesias that occurred in a 39-year-old female during five years of amitriptyline administration." | 1.26 | Amitriptyline-related peripheral neuropathy relieved during pyridoxine hydrochloride administration. ( Fredericks, S; Huff, MR; Meadows, GG, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (15.91) | 18.7374 |
| 1990's | 8 (18.18) | 18.2507 |
| 2000's | 15 (34.09) | 29.6817 |
| 2010's | 12 (27.27) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Genevois, AL | 1 |
| Ruel, J | 1 |
| Penalba, V | 1 |
| Hatton, S | 2 |
| Petitfils, C | 1 |
| Ducrocq, M | 1 |
| Principe, P | 1 |
| Dietrich, G | 1 |
| Greco, C | 2 |
| Delmas, P | 1 |
| Selvy, M | 1 |
| Pereira, B | 1 |
| Kerckhove, N | 1 |
| Busserolles, J | 1 |
| Farsi, F | 1 |
| Guastella, V | 1 |
| Merle, P | 1 |
| Pezet, D | 1 |
| Balayssac, D | 1 |
| Rossignol, J | 1 |
| Cozzi, B | 1 |
| Liebaert, F | 1 |
| Viallard, ML | 1 |
| Hermine, O | 1 |
| Yeo, B | 1 |
| Tey, HL | 1 |
| Liu, WQ | 1 |
| Kanungo, A | 1 |
| Toth, C | 1 |
| Gewandter, JS | 1 |
| Mohile, SG | 1 |
| Heckler, CE | 1 |
| Ryan, JL | 1 |
| Kirshner, JJ | 1 |
| Flynn, PJ | 1 |
| Hopkins, JO | 1 |
| Morrow, GR | 1 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 1 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 1 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 2 |
| Azadeh, N | 1 |
| Kelemen, K | 1 |
| Fonseca, R | 1 |
| Chu, SH | 1 |
| Lee, YJ | 1 |
| Lee, ES | 1 |
| Geng, Y | 1 |
| Wang, XS | 1 |
| Cleeland, CS | 1 |
| Dinat, N | 1 |
| Marinda, E | 1 |
| Moch, S | 1 |
| Rice, AS | 1 |
| Kamerman, PR | 1 |
| Beadles, WI | 1 |
| Jahn, A | 1 |
| Weigel, R | 1 |
| Clutterbuck, D | 1 |
| Kautio, AL | 2 |
| Haanpää, M | 2 |
| Leminen, A | 1 |
| Kalso, E | 2 |
| Kautiainen, H | 1 |
| Saarto, T | 2 |
| Lux, EA | 1 |
| Barton, DL | 1 |
| Wos, EJ | 1 |
| Qin, R | 1 |
| Mattar, BI | 1 |
| Green, NB | 1 |
| Lanier, KS | 1 |
| Bearden, JD | 1 |
| Kugler, JW | 1 |
| Hoff, KL | 1 |
| Reddy, PS | 1 |
| Rowland, KM | 1 |
| Riepl, M | 1 |
| Christensen, B | 1 |
| Gemignani, F | 1 |
| Ferrari, G | 1 |
| Vitetta, F | 1 |
| Giovanelli, M | 1 |
| Macaluso, C | 1 |
| Marbini, A | 1 |
| Song, Z | 1 |
| Meyerson, BA | 1 |
| Linderoth, B | 1 |
| Lauder, GR | 1 |
| White, MC | 1 |
| Lynch, ME | 1 |
| Clark, AJ | 1 |
| Sawynok, J | 1 |
| Sullivan, MJ | 1 |
| Veldhuijzen, DS | 2 |
| Kenemans, JL | 2 |
| van Wijck, AJ | 2 |
| Olivier, B | 2 |
| Kalkman, CJ | 2 |
| Volkerts, ER | 2 |
| McCarson, KE | 2 |
| Ralya, A | 1 |
| Reisman, SA | 2 |
| Enna, SJ | 2 |
| Duric, V | 1 |
| Winter, M | 1 |
| Verster, JC | 1 |
| Bastian, RW | 1 |
| Vaidya, AM | 1 |
| Delsupehe, KG | 1 |
| Gore, M | 1 |
| Dukes, E | 1 |
| Rowbotham, D | 1 |
| Tai, KS | 1 |
| Leslie, DL | 1 |
| Ho, KY | 1 |
| Huh, BK | 1 |
| White, WD | 1 |
| Yeh, CC | 1 |
| Miller, EJ | 1 |
| Millecamps, M | 1 |
| Coderre, TJ | 1 |
| Benbouzid, M | 1 |
| Choucair-Jaafar, N | 1 |
| Yalcin, I | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Meadows, GG | 1 |
| Huff, MR | 1 |
| Fredericks, S | 1 |
| Bondavalli, P | 1 |
| Parodi, A | 1 |
| Rebora, A | 1 |
| Vrethem, M | 1 |
| Boivie, J | 1 |
| Arnqvist, H | 1 |
| Holmgren, H | 1 |
| Lindström, T | 1 |
| Thorell, LH | 1 |
| Shlay, JC | 1 |
| Chaloner, K | 1 |
| Max, MB | 1 |
| Flaws, B | 1 |
| Reichelderfer, P | 1 |
| Wentworth, D | 1 |
| Hillman, S | 1 |
| Brizz, B | 1 |
| Cohn, DL | 1 |
| Kaptchuk, TJ | 1 |
| Ulett, GA | 1 |
| King, SA | 1 |
| Lein, B | 1 |
| Refaeian, M | 1 |
| King, JC | 1 |
| Dumitru, D | 1 |
| Davis, JL | 1 |
| Lewis, SB | 1 |
| Gerich, JE | 1 |
| Kaplan, RA | 1 |
| Schultz, TA | 1 |
| Wallin, JD | 1 |
| Vecht, CJ | 1 |
| Alting van Geusau, RB | 1 |
| Holmes, VF | 1 |
| Fricchione, GL | 1 |
| Zampollo, A | 1 |
| Sozzi, G | 1 |
| Basso, F | 1 |
| Niss, AI | 1 |
| Trubkovich, MIa | 1 |
| LeWitt, PA | 1 |
| Forno, LS | 1 |
| Lance, JW | 1 |
| Andrews, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies: Observational and Cross-sectional Study[NCT03854864] | 216 participants (Actual) | Observational | 2019-01-14 | Completed | |||
| Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)[NCT00471445] | Phase 3 | 462 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study[NCT00516503] | Phase 3 | 208 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief[NCT02265848] | Phase 4 | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine[NCT03096444] | Phase 2 | 13 participants (Actual) | Interventional | 2017-05-23 | Terminated (stopped due to Efficacy was not seen after interim analysis) | ||
| The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients[NCT00000817] | 260 participants (Actual) | Interventional | 1994-11-30 | Completed | |||
| A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection[NCT00000793] | Phase 2 | 240 participants | Interventional | Completed | |||
| A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy[NCT00000842] | Phase 2 | 270 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cancer survivors who completed chemotherapy at least 1 month prior and had Chemotherapy Induced Peripheral Neuropathy (CIPN) (greater than or equal to 4 out of 10) were enrolled. CIPN was assessed using average scores from a 7-day daily diary that asks patients to rate the average pain, numbness, or tingling in their hands and feet over the past 24 hours on an 11-point numeric rating scale at baseline and 6 weeks post intervention. CIPN ranges from 0 (no pain) to 10 (worst possible pain)." (NCT00471445)
Timeframe: Week 6 - Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 6 | |
| Ketamine/Amitriptyline NP-H Cream | 6.55 | 4.93 |
| Placebo Cream | 6.47 | 5.19 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the autonomic neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | (units on a scale)*week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 85.0 |
| Placebo | 86.8 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The secondary analysis was to compare changes from baseline at 4 weeks for the motor neuropathy subscale of the CIPN-20. To analyze this endpoint, the area under the curve (AUC) from baseline to week 4 was calculated for each patient's motor neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From Baseline to week 4
| Intervention | (units on a scale)* week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 69.2 |
| Placebo | 70.1 |
The Peripheral Neuropathy Questionnaire was used to analyze this endpoint. Patient neuropathy symptoms were scored on a 0 - 100 scale (higher score represents less symptomatic). The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | units on a scale * week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 172.6 |
| Placebo | 175.7 |
The scoring algorithm for the parent instrument, the EORTC QLQ-C30, was applied for linearly converting items and subscales of CIPN-20 to 0-100 scales so that a high score corresponds to better condition or less symptom. The primary analysis was the change in sensory neuropathy subscale of the CIPN-20 from baseline to week 4. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's sensory neuropathy score. The average AUC for the placebo arm was compared to the average AUC for the topical amitriptyline HCl/ baclofen/ ketamine arm using a Wilcoxon rank sum test. (NCT00516503)
Timeframe: From baseline to 4 weeks
| Intervention | (units on a scale) * week (Mean) |
|---|---|
| Baclofen-amitriptyline Hydrochloride-ketamine | 61.0 |
| Placebo | 60.9 |
Frequency and severity of adverse events reported by patients in weekly diary and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Grade 3+ Adverse Event | Grade 4+ Adverse Event | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 8 | 1 |
| Placebo | 5 | 1 |
Each mood scale (0 - 100, higher is better mood) will be analyzed as an endpoint along with the total mood disturbance score. (NCT00516503)
Timeframe: At 4 weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| POMS Tension-Anxiety Subscale | POMS VA Subscale | POMS Anger-Hostility Score | POMS Confusion-Bewilderment | POMS Depression-Dejection Score | POMS Fatigue-Inertia Score | Mean POMS Score | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 83.2 | 31.1 | 87.8 | 76.9 | 86.4 | 67.2 | 71.5 |
| Placebo | 83.0 | 33.0 | 87.7 | 77.9 | 85.8 | 63.6 | 71.8 |
Pain severity, defined by the four items addressing worst, least, and average pain and pain right now as measured by the BPI will be analyzed identical to the primary endpoint. Additionally, total pain interference as measured by the BPI will be transformed onto a 0-100 ( higher is less pain) point scale. The area under the curve (AUC) from baseline to week 4 was calculated for each patient's score. The average AUC for the placebo arm and the topical amitriptyline HCl/ baclofen/ ketamine arm are reported. (NCT00516503)
Timeframe: Up to 4 weeks
| Intervention | units on a scale * week (Mean) | |||
|---|---|---|---|---|
| Worst Pain | Least Pain | Average Pain | BPI Total Interference | |
| Baclofen-amitriptyline Hydrochloride-ketamine | 58.1 | 78.0 | 66.4 | 76.5 |
| Placebo | 58.7 | 77.3 | 65.4 | 77.3 |
Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Average Baseline NPRS Score | Average NPRS after 1000 Hz. stimulation | Average NPRS after standard stimulation | Average NPRS after Wash off | Best Baseline NPRS score | Best NPRS score after 1000 Hz. stimulation | Best NPRS score after standard stimulation | Best NPRS after Wash off | Worst Baseline NPRS score | Worst NPRS score after 1000 Hz. stimulation | Worst NPRS score after standard stimulation | Worst NPRS after Wash off | |
| Treatment Group A | 6.09 | 3.73 | 5.64 | 6.45 | 3.72 | 2.64 | 3.46 | 4.54 | 7.90 | 6.64 | 8.18 | 8.72 |
| Treatment Group B | 6.27 | 3.82 | 6.09 | 7.18 | 4.45 | 2.18 | 4.45 | 5.36 | 8.09 | 6.64 | 8.36 | 8.81 |
ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline ODI score | ODI after 1000 Hz. stimluation | ODI after standard stimulation | ODI after wash off | |
| Treatment Group A | 47.49 | 39.23 | 49.63 | 52.87 |
| Treatment Group B | 51.25 | 33.77 | 49.05 | 56.77 |
PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4. (NCT02265848)
Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| PGIC After 1000 Hz. stimulation | PGIC after standard stimulation | PGIC after Wash off | |
| Treatment Group A | 4.27 | 2.54 | 1.45 |
| Treatment Group B | 5.91 | 2.45 | 1.27 |
At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one. (NCT02265848)
Timeframe: End of treatment visit on visit 4
| Intervention | participants (Number) | |
|---|---|---|
| Subjects who prefer 1000 Hz. stimulation | Subjects who prefer standard stimulation | |
| Treatment Group A | 8 | 3 |
| Treatment Group B | 10 | 1 |
"Peak itch intensity between the vehicle and 4 other active treatments (individual ketamine, amitriptyline, or lidocaine, and KeAmLi-combo). Itch intensity was measured on a 100mm scale visual analog scale for 10 minutes. 0 was weighted with no itch and 100 was weighted with most itch imaginable." (NCT03096444)
Timeframe: 10 minutes
| Intervention | Intensity score (Mean) |
|---|---|
| Topical KeAmLi Combo | 62.7 |
| Topical Ketamine | 63.1 |
| Topical Amitriptyline | 69.2 |
| Topical Lidocaine | 65.8 |
| Topical Vehicle | 61.9 |
Assess mechanical detection and pain thresholds using von Frey filaments stimulators (measured in force mN) to calculate the final threshold as the geometric mean of five series of ascending and descending stimuli. (NCT03096444)
Timeframe: 5 minutes
| Intervention | mN (Mean) | |
|---|---|---|
| Mechanical Detection Threshold | Mechanical Pain Threshold | |
| Topical Amitriptyline | 3.573423965 | 152.4768146 |
| Topical KeAmLi Combo | 3.519376956 | 152.3293608 |
| Topical Ketamine | 3.464204768 | 135.9 |
| Topical Lidocaine | 3.546037659 | 126.9 |
| Topical Vehicle | 3.525692637 | 148.7138273 |
Two standardized quantitative sensory tests are performed to measure warmth detection threshold (assesses the threshold of which warmth sensation is first detected) and heat pain threshold (assesses the threshold at which heat pain sensation is first detected). Measured in change in celsius. (NCT03096444)
Timeframe: 3 minutes
| Intervention | Degrees celsius (Mean) | |
|---|---|---|
| Warm Detection Threshold | Heat Pain Threshold | |
| Topical Amitriptyline | 33.9 | 40.0 |
| Topical KeAmLi Combo | 33.6 | 39.8 |
| Topical Ketamine | 34.0 | 40.0 |
| Topical Lidocaine | 33.7 | 39.4 |
| Topical Vehicle | 33.8 | 39.7 |
4 reviews available for amitriptyline and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezo | 2015 |
Isolated sural neuropathy presenting as lateral ankle pain.
Topics: Accidents, Occupational; Adult; Amitriptyline; Analgesics, Non-Narcotic; Ankle; Anti-Inflammatory Ag | 2001 |
[Drug treatment of pain originating from the peripheral nervous system].
Topics: Amitriptyline; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerve Block; H | 1990 |
13 trials available for amitriptyline and Peripheral Nerve Diseases
| Article | Year |
|---|---|
High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies.
Topics: Administration, Cutaneous; Administration, Topical; Aged; Aged, 80 and over; Amitriptyline; Analgesi | 2019 |
Equivalency of tricyclic antidepressants in open-label neuropathic pain study.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Drug Therapy, Combination; Female; Humans; Male; Mi | 2014 |
A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
Topics: Administration, Topical; Adult; Aged; Amitriptyline; Antineoplastic Agents; Double-Blind Method; Fem | 2014 |
Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy.
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anti-Retroviral Agents; Cross-Over Studies; Double-B | 2015 |
Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.
Topics: Adult; Aged; Amitriptyline; Antineoplastic Agents; Double-Blind Method; Female; Humans; Male; Middle | 2009 |
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Aged; Amitriptyline; Antineoplastic Agents; | 2011 |
Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study.
Topics: Adenosine; Administration, Topical; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Analg | 2005 |
Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings.
Topics: Adult; Amitriptyline; Antidepressive Agents; Attention; Cross-Over Studies; Double-Blind Method; Ele | 2006 |
Acute and subchronic effects of amitriptyline 25mg on actual driving in chronic neuropathic pain patients.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Attention; Automobile Driving; Chronic Disea | 2006 |
Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Depression; Dou | 2008 |
Topical amitriptyline versus lidocaine in the treatment of neuropathic pain.
Topics: Administration, Topical; Amitriptyline; Analgesics, Non-Narcotic; Anesthetics, Local; Double-Blind M | 2008 |
A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cross-Over Studies; | 1997 |
Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Acupuncture Therapy; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Double-Blind Method; Fe | 1998 |
27 other studies available for amitriptyline and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Analgesic Effects of Topical Amitriptyline in Patients With Chemotherapy-Induced Peripheral Neuropathy: Mechanistic Insights From Studies in Mice.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Analgesics, Non- | 2021 |
Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
Topics: Adult; Amitriptyline; Antineoplastic Agents; Calcium; Cross-Sectional Studies; Duloxetine Hydrochlor | 2021 |
Effective treatment of notalgia paresthetica with amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Humans; Male; Middle Aged; Peripheral Nervous Syste | 2013 |
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Antiretroviral Therapy, Highly Active; Cross-Sectional Stud | 2009 |
Case report: successful treatment of a patient with trigeminal neuropathy using ziconotide.
Topics: Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Azabicyclo Compounds; Calcium Channel B | 2010 |
Non-length-dependent small fibre neuropathy. Confocal microscopy study of the corneal innervation.
Topics: Adult; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Second-Generation; Antidepressive A | 2010 |
The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; C | 2011 |
Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cerebral Palsy; Chi | 2005 |
Amitriptyline prevents thermal hyperalgesia and modifications in rat spinal cord GABA(B) receptor expression and function in an animal model of neuropathic pain.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Animals; Hot Temperature; Hyperalgesia; Male; Pain Threshol | 2005 |
GABA(B) receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2006 |
Sensory neuropathic cough: a common and treatable cause of chronic cough.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amitriptyline; Bronchial Provocation Tests; Bronchoscopy; | 2006 |
Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Amitriptyline; Analgesics; Analgesics, | 2006 |
Rats with chronic post-ischemia pain exhibit an analgesic sensitivity profile similar to human patients with complex regional pain syndrome--type I.
Topics: Amitriptyline; Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dos | 2008 |
Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain; Chronic Di | 2008 |
Amitriptyline-related peripheral neuropathy relieved during pyridoxine hydrochloride administration.
Topics: Adult; Amitriptyline; Humans; Lithium; Male; Paresthesia; Peripheral Nervous System Diseases; Pyrido | 1982 |
Peripheral neuropathy in scleroderma successfully treated with amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Female; Humans; Middle Aged; Peripheral Nervous Sys | 1997 |
Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain.
Topics: Acupuncture Therapy; Amitriptyline; Antidepressive Agents, Tricyclic; HIV Infections; Humans; Pain; | 1999 |
Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain.
Topics: Acupuncture Therapy; Amitriptyline; Antidepressive Agents, Tricyclic; HIV Infections; Humans; Pain; | 1999 |
Acupuncture and amitriptyline for HIV-related peripheral neuropathic pain.
Topics: Acupuncture Therapy; Amitriptyline; Antidepressive Agents, Tricyclic; Drug Administration Schedule; | 1999 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Potential therapy for painful neuropathy.
Topics: Acupuncture Therapy; Amitriptyline; HIV Infections; Humans; Mexiletine; Nerve Growth Factors; Pain; | 1995 |
Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine.
Topics: Adult; Aged; Amitriptyline; Diabetic Neuropathies; Drug Therapy, Combination; Female; Fluphenazine; | 1977 |
Hypomania in an AIDS patient receiving amitriptyline for neuropathic pain.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amitriptyline; Humans; Male; Mood Disorders; Palliative C | 1989 |
Amitriptyline-related peripheral neuropathy. Case report.
Topics: Amitriptyline; Humans; Male; Middle Aged; Peripheral Nervous System Diseases | 1988 |
[Various rarely encountered adverse effects and complications of psychopharmacotherapy].
Topics: Adult; Agnosia; Amitriptyline; Apraxias; Brain Diseases; Cerebral Cortex; Haloperidol; Humans; Male; | 1985 |
Peripheral neuropathy following amitriptyline overdose.
Topics: Amitriptyline; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Suicide, Attempted; Su | 1985 |
Dysaesthesia-dyskinesia: a syndrome of painful legs and moving toes.
Topics: Aged; Amantadine; Amitriptyline; Chlorpromazine; Dihydroxyphenylalanine; Female; Humans; Leg; Moveme | 1973 |